Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$150.90 USD
+1.28 (0.86%)
Updated May 22, 2024 04:00 PM ET
After-Market: $150.82 -0.08 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 301 - 320 ( 407 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Based on Significant Clinical Progress and Prioritization of Resources, Increasing Target to $19
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Based on Significant Clinical Progress and Prioritization of Resources, Increasing Target to $19
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Announces Issuance of Patent for its Second Generation LNP Delivery Platform
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Announces Issuance of Patent for its Second Generation LNP Delivery Platform
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Conversation with Alnylam CEO Highlights Strategic Vision and Plans for 2012
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Conversation with Alnylam CEO Highlights Strategic Vision and Plans for 2012
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Announces Strategic Corporate Restructuring To Focus on Key Pipeline Opportunities
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Announces Strategic Corporate Restructuring To Focus on Key Pipeline Opportunities
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Files Phase I Clinical Trial Application for ALN-TTR02
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Files Phase I Clinical Trial Application for ALN-TTR02
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Reports Positive Preliminary Phase I Results for ALN-PCS
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Reports Positive Preliminary Phase I Results for ALN-PCS
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Presents Data for its Hematology Programs at ASH and Regulus Initiates a Brain Cancer Program
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Presents Data for its Hematology Programs at ASH and Regulus Initiates a Brain Cancer Program
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A Key Opinion Leaders Thoughts on the State of ATTR and Alnylams ALN-TTR Program
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M